Literature DB >> 14717813

Intravenous iron and the risk of infection in end-stage renal disease patients.

Ursula C Brewster1, Mark A Perazella.   

Abstract

Oral iron is typically insufficient for the iron deficiency of hemodialysis patients. Intravenous (IV) iron is well tolerated by most patients and non-dextran-containing iron preparations are associated with few allergic reactions. However, there is the potential for an increased risk of infection with IV iron that appears to increase bacterial growth as well as inhibit the host's innate immune response to bacterial infection. Clinical studies suggest a link between iron therapy and infection. Practicing nephrologists should be aware of this issue, but should not hesitate to use IV iron in iron-deficient patients while avoiding the development of iron overload and administration of iron to patients who have active infection.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14717813     DOI: 10.1111/j.1525-139x.2004.17115.x

Source DB:  PubMed          Journal:  Semin Dial        ISSN: 0894-0959            Impact factor:   3.455


  8 in total

1.  Effect of intravenous iron use on hospitalizations in patients undergoing hemodialysis: a comparative effectiveness analysis from the DEcIDE-ESRD study.

Authors:  Navdeep Tangri; Dana C Miskulin; Jing Zhou; Karen Bandeen-Roche; Wieneke M Michels; Patti L Ephraim; Aidan McDermott; Deidra C Crews; Julia J Scialla; Stephen M Sozio; Tariq Shafi; Bernard G Jaar; Klemens Meyer; L Ebony Boulware
Journal:  Nephrol Dial Transplant       Date:  2014-11-02       Impact factor: 5.992

Review 2.  Iron and infection in hemodialysis patients.

Authors:  Julie H Ishida; Kirsten L Johansen
Journal:  Semin Dial       Date:  2013-12-12       Impact factor: 3.455

3.  Pretransplantation erythropoiesis-stimulating agent hyporesponsiveness is associated with increased kidney allograft failure and mortality.

Authors:  Nadiesda A Costa; Abhijit V Kshirsagar; Lily Wang; Randal K Detwiler; M Alan Brookhart
Journal:  Transplantation       Date:  2013-11-15       Impact factor: 4.939

4.  Infection risk with bolus versus maintenance iron supplementation in hemodialysis patients.

Authors:  M Alan Brookhart; Janet K Freburger; Alan R Ellis; Lily Wang; Wolfgang C Winkelmayer; Abhijit V Kshirsagar
Journal:  J Am Soc Nephrol       Date:  2013-06-20       Impact factor: 10.121

5.  Iron supplementation and mortality in incident dialysis patients: an observational study.

Authors:  Emanuel Zitt; Gisela Sturm; Florian Kronenberg; Ulrich Neyer; Florian Knoll; Karl Lhotta; Günter Weiss
Journal:  PLoS One       Date:  2014-12-02       Impact factor: 3.240

Review 6.  Oxidative Stress and Cardiovascular Complications in Chronic Kidney Disease, the Impact of Anaemia.

Authors:  Faisal Nuhu; Sunil Bhandari
Journal:  Pharmaceuticals (Basel)       Date:  2018-10-11

7.  Heme iron polypeptide for the treatment of iron deficiency anemia in non-dialysis chronic kidney disease patients: a randomized controlled trial.

Authors:  Shankar P Nagaraju; Adam Cohn; Ayub Akbari; Janet L Davis; Deborah L Zimmerman
Journal:  BMC Nephrol       Date:  2013-03-20       Impact factor: 2.388

8.  Comparative short-term safety of bolus versus maintenance iron dosing in hemodialysis patients: a replication study.

Authors:  Janet K Freburger; Alan R Ellis; Abhijit V Kshirsagar; Lily Wang; M Alan Brookhart
Journal:  BMC Nephrol       Date:  2014-09-22       Impact factor: 2.388

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.